Liquidia Corporation General and Administrative Expenses | LQDA

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Liquidia Corporation

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
157 M	81.6 M	44.7 M	32.4 M	23.1 M	27.4 M	13.6 M	8.75 M	10.2 M	4.84 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
157 M	4.84 M	40.4 M

Quarterly General and Administrative Expenses Liquidia Corporation

2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
38.8 M	46.9 M	-	40.1 M	38.8 M	30.1 M	-	20.2 M	19.9 M	20.2 M	-	10.6 M	9.24 M	7.79 M	-	6.74 M	6.94 M	12.5 M	-	4.88 M	4.42 M	5.34 M	-	7.15 M	5.23 M	3.82 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
46.9 M	3.82 M	17 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Cullinan Management CGEM	54.2 M	$ 16.04	3.42 %	$ 966 M	USA
Compugen Ltd. CGEN	8.89 M	$ 2.31	0.43 %	$ 216 M	Israel
Coherus BioSciences CHRS	101 M	$ 1.12	0.86 %	$ 131 M	USA
Celldex Therapeutics CLDX	43.8 M	$ 32.59	2.97 %	$ 2.16 B	USA
CollPlant Biotechnologies Ltd. CLGN	4.83 M	$ 3.41	1.46 %	$ 41.6 M	Israel
Cellectis S.A. CLLS	19.8 M	$ 1.41	0.48 %	$ 141 M	France
Cellectar Biosciences CLRB	11.5 M	$ 1.67	0.56 %	$ 4.36 M	USA
CNS Pharmaceuticals CNSP	6.21 M	$ 5.3	0.7 %	$ 2.35 M	USA
Cocrystal Pharma COCP	3.96 M	$ 1.11	1.72 %	$ 12.5 M	USA
Collegium Pharmaceutical COLL	67.6 M	$ 21.87	0.05 %	$ 692 M	USA
Corcept Therapeutics Incorporated CORT	449 M	$ 122.03	4.99 %	$ 12.7 B	USA
Corbus Pharmaceuticals Holdings CRBP	15.2 M	$ 5.85	0.16 %	$ 77.9 M	USA
Cardiff Oncology CRDF	14.2 M	$ 1.14	1.79 %	$ 76.2 M	USA
Curis CRIS	14 M	$ 0.79	0.1 %	$ 10.4 M	USA
CorMedix CRMD	68.2 M	$ 7.26	0.97 %	$ 523 K	USA
CRISPR Therapeutics AG CRSP	73.5 M	$ 57.34	3.45 %	$ 5.16 B	Schweiz
Corvus Pharmaceuticals CRVS	9.25 M	$ 10.74	0.09 %	$ 848 M	USA
Champions Oncology CSBR	11.2 M	$ 4.97	0.61 %	$ 68.7 M	USA
CytomX Therapeutics CTMX	29.8 M	$ 2.58	0.78 %	$ 356 M	USA
Citius Pharmaceuticals CTXR	18.5 M	$ 0.52	0.4 %	$ 5.75 M	USA
Cue Biopharma CUE	16.2 M	$ 24.36	1.27 %	$ 2.31 B	USA
CEL-SCI Corporation CVM	8.92 M	$ 2.42	4.76 %	$ 19.4 M	USA
Cytokinetics, Incorporated CYTK	284 M	$ 62.7	0.2 %	$ 7.53 M	USA
Daré Bioscience DARE	8.76 M	$ 0.84	0.04 %	$ 9.39 M	USA
DBV Technologies S.A. DBVT	32.8 M	$ 10.44	0.47 %	$ 1.46 B	France
DiaMedica Therapeutics DMAC	9.78 M	$ 8.42	2.31 %	$ 396 M	USA
Denali Therapeutics DNLI	137 M	$ 19.91	0.41 %	$ 3.44 B	USA
Precision BioSciences DTIL	32.2 M	$ 6.31	0.16 %	$ 80.9 M	USA
Dyadic International DYAI	890 K	$ 0.45	0.31 %	$ 16.3 M	USA
Editas Medicine EDIT	49.9 M	$ 2.79	6.49 %	$ 248 M	USA
Edesa Biotech EDSA	4.24 M	$ 3.91	1.3 %	$ 22.2 M	USA
Enlivex Therapeutics Ltd. ENLV	186 K	$ 0.36	0.36 %	$ 16.5 M	Israel
Enanta Pharmaceuticals ENTA	43.9 M	$ 12.6	0.93 %	$ 269 K	USA
Entera Bio Ltd. ENTX	5.52 M	$ 2.62	0.69 %	$ 121 M	Israel
Equillium EQ	10.8 M	$ 1.45	2.84 %	$ 83.1 M	USA
Eton Pharmaceuticals ETON	35.8 M	$ 55.62	0.47 %	$ 1.5 B	USA
Evogene Ltd. EVGN	4.29 M	$ 0.4	3.54 %	$ 3.15 M	Israel
Exelixis EXEL	519 M	$ 58.85	0.79 %	$ 16 B	USA
EyePoint Pharmaceuticals EYPT	51.6 M	$ 3.15	0.62 %	$ 231 K	USA
Fate Therapeutics FATE	46.5 M	$ 2.43	4.74 %	$ 289 M	USA
Fortress Biotech FBIO	96.4 M	$ 2.09	2.96 %	$ 58.3 M	USA
Fennec Pharmaceuticals FENC	28.3 M	$ 10.62	4.12 %	$ 303 M	USA
Fulcrum Therapeutics FULC	28.7 M	$ 3.71	0.54 %	$ 235 M	USA
Merus N.V. MRUS	82.8 M	-	-	$ 5.78 B	Niderland
Galectin Therapeutics GALT	5.8 M	$ 3.73	3.72 %	$ 238 M	USA
Geron Corporation GERN	159 M	$ 1.21	0.83 %	$ 807 M	USA
Gilead Sciences GILD	5.77 B	$ 144.63	0.85 %	$ 180 B	USA
Greenwich LifeSciences GLSI	2.23 M	$ 16.91	0.77 %	$ 229 M	USA
Genmab A/S GMAB	661 M	$ 38.48	10.73 %	$ 2.49 B	Danmark
Genprex GNPX	6.09 M	$ 2.72	3.42 %	$ 2.54 M	USA